【导读】14日12板合富中国核查完毕，宣布明日开市起复牌 中国基金报记者 晨曦 14日12板大牛股合富中国，即将复牌！ 11月19日盘后，合富中国发布关于股票交易停牌核查结果暨复牌的公告。 合富中国称，近期，公司就股票交易异常波动及严重异常波动的相关事项进行了核查。鉴于相关核查工 作已完成，经向上海证券交易所申请，公司股票将于2025年11月20日（星期四）开市起复牌。 当前股价存在明显泡沫化特征 作为近期超级牛股，合富中国在10月28日至11月14日期间走出"14天12板"，累计涨幅高达256.29%，引 发市场关注。停牌前，合富中国股价收于23.8元/股，总市值为95亿元。 | 证券代码 | 证券简称 | 停复牌类型 | 停牌起 | 停牌 | 停牌终止日 | 复牌日 | | --- | --- | --- | --- | --- | --- | --- | | | | | 始日 | 期间 | | | | 603122 | 合富中国 | A 股 复牌 | | | 2025/11/19 | 2025/11/20 | 来看详情—— 不存在应披露而未披露信息 合富中国称，经公司自查，并向公司控股股东和间接控股股东 ...

【导读】14日12板合富中国核查完毕，宣布明日开市起复牌 14日12板大牛股合富中国，即将复牌！ 11月19日盘后，合富中国（603122）发布关于股票交易停牌核查结果暨复牌的公告。 合富中国称，近期，公司就股票交易异常波动及严重异常波动的相关事项进行了核查。鉴于相关核查工作已完成，经向上海证券交易所申请，公司股票将 于2025年11月20日（星期四）开市起复牌。 | 证券代码 | 证券简称 | 停复牌类型 | 停牌起 | 停牌 | 停牌终止日 | 复牌日 | | --- | --- | --- | --- | --- | --- | --- | | | | | 始日 | 期间 | | | | 603122 | 合富中国 | A 股 复牌 | | | 2025/11/19 | 2025/11/20 | 来看详情—— 当前股价存在明显泡沫化特征 作为近期超级牛股，合富中国在10月28日至11月14日期间走出"14天12板"，累计涨幅高达256.29%，引发市场关注。停牌前，合富中国股价收于23.8元/ 股，总市值为95亿元。 合富中国称，经公司自查，并向公司控股股东和间接控股股东核实，截至公告披露日，除了在指定 ...

【导读】14日12板合富中国核查完毕，宣布明日开市起复牌 中国基金报记者 晨曦 | 证券代码 | 证券简称 | 停复牌类型 | 停牌起 | 停牌 | 停牌终止日 | 复牌日 | | --- | --- | --- | --- | --- | --- | --- | | | | | 始日 | 期间 | | | | 603122 | 合富中国 | A 股 复牌 | | | 2025/11/19 | 2025/11/20 | 14日12板大牛股合富中国，即将复牌！ 11月19日盘后，合富中国发布关于股票交易停牌核查结果暨复牌的公告。 合富中国称，近期，公司就股票交易异常波动及严重异常波动的相关事项进行了核查。鉴于相关核查工作已完成，经向上海证券交易所申 请，公司股票将于2025年11月20日（星期四）开市起复牌。 此外，合富中国表示，公司未发现其他有可能对公司股价产生较大影响的重大事件。公司董事、高级管理人员、控股股东及间接控股股东 在公司本次股票交易异常波动期间不存在买卖公司股票的情况。 同时，合富中国提醒称，公司主营业务未发生重大变化，且处于亏损状态。股价短期内连续上涨，存在市场情绪过热、非理性炒作风险； 股价 ...

Core Insights - The three principles proposed by the founder of Yidu Technology, Ms. Gong Rujing, emphasize that AI should not replace doctors, should remain contextually relevant, and should not abandon inclusivity in healthcare [1][9] - The forum held in Kuala Lumpur gathered global investment leaders and industry experts to discuss the future of AI in healthcare [1] Group 1: AI in Healthcare - Ms. Gong Rujing highlighted that there is no "universal AI," but rather precise solutions that fit into workflows, emphasizing the need for high-quality medical data and seamless integration into the entire diagnostic and treatment process [3][4] - Yidu Technology's "AI Medical Brain" YiduCore has processed over 6 billion medical records, establishing a robust foundation for AI applications in healthcare [4] - The company has developed over 1,000 intelligent agents covering various clinical needs, significantly improving efficiency and standardization in areas like oncology [4][6] Group 2: Inclusivity in Healthcare - The ultimate mission of AI in healthcare is to provide accessible and affordable health services to everyone, as stated by Ms. Gong Rujing [6] - Yidu Technology has participated in the development of health insurance projects across multiple provinces, offering insurance products with annual premiums as low as 100 yuan, benefiting millions [6][7] - The company has served over 40 million insured users, demonstrating the social equity driven by technology [6] Group 3: Globalization and Localization - Ms. Gong Rujing emphasized that globalization in AI healthcare should not be a mere replication of solutions but should involve "technology generalization + local adaptation" to create value with local partners [8] - Yidu Technology has implemented localized projects, such as the BruHealth digital health platform in Brunei, covering over 60% of the population [8] - The company is also involved in Singapore's "MIC@Home" project, supporting remote monitoring and management of discharged patients [8]

AI医疗是一个比较宽泛的概念，我们可以这样理解：所有利用AI算法，结合医疗、医药的海量数据，最 终在这个垂类场景落地的AI应用，都基本可以定义成AI医疗。 人工智能正加速赋能千行百业，医疗领域无疑是其最具潜力的重要应用方向之一。 近期，《关于促进和规范"人工智能+医疗卫生"应用发展的实施意见》正式印发。这份被业内视为"AI医 疗施工图"的政策文件，系统明确了八大重点应用领域，涵盖"人工智能+基层应用""人工智能+临床诊 疗""人工智能+患者服务"以及"人工智能+中医药"等多个方面，并提出了2027年与2030年两阶段发展目 标，为AI医疗产业规划出清晰的发展路径。 显然，一幅更加智慧、普惠、安全的医疗未来发展蓝图正徐徐展开。近日，长城消费增值基金经理龙宇 飞做客央视财经直播间，围绕AI医疗产业的发展进程、最新政策影响及其投资逻辑等话题展开深度交 流。以下是其核心观点： 1、与传统医疗信息化相比，AI的介入是一种质变，它能从海量数据中挖掘规 律、形成洞察、甚至做出辅助诊断。 2、当前AI医疗整体正处于从技术验证向规模落地、探索商业模式过渡的阶段， 而《关于促进和规范"人工智能+医疗卫生"应用发展的实施意见》的发 ...

行情回顾及主要观点： 上周A股市场整体呈现下跌：沪深300跌1.1%，中证500跌1.3%，中证1000跌1.5%，创业板50跌3.7%， 科创50跌3.8%。交易面，A股市场上周日均成交额在2万亿元左右，市场交投活跃。市场热点呈现快速 轮动特征，大消费、医药、化工、油气等板块交替活跃，电子、通信等科技权重板块回调较深。建议短 期内关注需求修复与政策共振、估值相对较低的景气成长领域，把握业绩弹性和产业升级主线，如受益 于储能订单爆发及技术创新突破的锂电池板块，借道新能源含量38%的创业板50ETF（159949）等布局 相关产业。 创业板为主要"三创（创新、创造、创意）四新（新技术、新产业、新业态、新模式）"的成长型创新创 业企业提供直接融资平台。权重行业方面，创业板50指数聚焦信息技术+新能源+金融科技+医药四大新 质生产力赛道，科技成长属性纯粹。 图：创业板50指数四大赛道 医药板块上周大幅反弹。创新药医保谈判预期改善、ADC/GLP-1等赛道活跃、ESMO会议催化创新药数 据披露等多重利好共振。中长期来看，创新药出海（2025年BD交易额高增）、医保支付改革、AI医疗 应用（如内镜机器人）等有望成为医药 ...

11月17日晚间，创业慧康（300451.SZ）披露股东权益变动，杭州更好智投管理咨询合伙企业（有限合 伙）（以下简称"杭州更好"）将通过股份受让、表决权委托、提名董事等方式，成为创业慧康的控股股 东，创业慧康仍处于无实控人状态。 长江商报消息 ●长江商报记者 徐佳 长江商报记者注意到，杭州更好的背后是港股上市公司华检医疗（01931.HK）。而耗资5亿元拿下创业 慧康控股权，华检医疗意在借助创业慧康近30年的行业积淀与前瞻性的AI布局，落地AI医疗战略。 港股上市公司并购A股公司再添重磅案例。 另一方面，华检医疗的收购也面临多重风险。继2024年业绩转亏之后，2025年前三季度，创业慧康实现 营业收入8.62亿元，同比下降26.26%；归属于上市公司股东的净利润（以下简称"归母净利润"）亏损 1.22亿元，同比下降331.69%。近两年，创业慧康归母净利润累计亏损2.96亿元。 创业慧康本次易主将分三步进行。 第一步，创业慧康原第一大股东葛航将其所持上市公司9652.51万股股份转让给杭州更好，占上市公司 总股本的6.23%。本次交易中，创业慧康每股作价5.18元，交易总金额为5亿元。 第二步，杭州更好分别 ...

Core Viewpoint - The company is accelerating its overseas expansion through acquisitions, with a recent agreement to acquire 100% of Da Zhong Tang in Singapore, marking a significant step in its strategy to internationalize traditional Chinese medicine [4][5]. Group 1: Acquisition and Expansion - The company announced the acquisition of Da Zhong Tang, which operates 14 traditional Chinese medicine clinics in Singapore, enhancing its local service capabilities and user trust [4][5]. - This acquisition follows a strategic partnership with a digital healthcare platform, indicating a robust approach to expanding its market presence in Singapore through a combination of acquisitions, partnerships, and self-built initiatives [5]. Group 2: AI Development in Traditional Medicine - The company is developing AI representations of renowned doctors, leveraging extensive clinical data to replicate expert diagnostic capabilities and enhance patient care [6]. - The AI system, based on deep learning algorithms, aims to facilitate knowledge transfer from top experts to junior doctors, thereby improving the efficiency of medical resource allocation and accelerating revenue growth [6].

近日，商汤医疗完成数亿元新一轮战略融资，本轮投资方包括联想创投、联创资本、九弦资本、申冉投 资等多家知名投资机构。这一融资进展印证了市场对商汤医疗领先技术实力、成熟商业模式及价值增长 潜力的高度认可。 今年年初，商汤医疗已获得美的系盈峰控股、人民卫生出版社集团旗下人卫科技发展公司等机构的上亿 元投资。产业方的联合赋能，正推动商汤医疗AI技术在真实医疗场景中加速融合迭代，成功搭建起从 技术研发到产业落地的关键桥梁。目前，商汤医疗已同步启动A轮融资，认购金额超5亿，投后估值超 30亿，融资规模与品牌影响力稳步攀升。 ...

Group 1 - The core point of the news is the change of control at Chuangye Huikang, with Hangzhou Genghao becoming the largest shareholder due to the debt crisis faced by founder Ge Hang [2][4] - The transaction involves Ge Hang transferring 6.23% of shares to Hangzhou Genghao for 500 million yuan, along with the delegation of voting rights for an additional 10.06% of shares [3] - Following this transaction, Hangzhou Genghao will hold a total of 12.64% of the voting rights, allowing it to nominate a majority of the board members and effectively control Chuangye Huikang [3] Group 2 - Ge Hang's debt crisis has escalated, leading to a series of share transfers and judicial freezes, resulting in a "no owner" phase for Chuangye Huikang [4][5] - The company has faced declining performance, with a projected first loss since its listing in 2024, and its market value has decreased from a peak of 25.2 billion yuan to 8.5 billion yuan [5] - The medical information industry is undergoing significant changes, with many companies facing operational challenges, including Chuangye Huikang, which is experiencing a control change amid a broader industry downturn [6] Group 3 - The acquisition by Hangzhou Genghao is seen as a strategic move to leverage AI capabilities in the medical field, as Chuangye Huikang has a substantial data foundation for AI model training [8] - Despite previous diversification attempts, over 90% of Chuangye Huikang's revenue still comes from the medical sector, indicating limited success in expanding beyond its core business [7][8]